Introduction
============

Amantadine is an antiviral and antiparkinsonian drug associated with rare episodes of bilateral corneal edema, which often resolves upon cessation of the medication.[@b1-opth-12-1367] Endothelial cell loss may require corneal transplantation even after discontinuation of amantadine.[@b2-opth-12-1367] Although cases have been temporally associated with amantadine and its cessation, national data suggest a higher frequency of new diagnoses of Fuchs dystrophy among individuals starting amantadine therapy.[@b3-opth-12-1367] To date, the causes of corneal edema are unclear; therefore, we sought to investigate the clinical and genetic features associated with amantadine-associated edema in a 44-year-old woman who presented with bilateral corneal edema.

Patient and methods
===================

A 44-year-old female presented with decreased vision in both eyes over the course of 2 weeks, at which time she only utilized topical loteprednol 0.5% twice daily in both eyes for blepharitis. She also took amantadine 400 mg daily by mouth for over 3 years in the setting of ataxic cerebral palsy and associated neurological complications. Best corrected visual acuity at baseline was measured four months prior to presentation at 20/25 in both eyes (oculus uterque \[OU\]).

At the time of presentation, visual acuity was 20/125 in the right eye (oculus dextrus \[OD\]) and 20/60 in the left eye (oculus sinister \[OS\]). Pentacam Scheimpflug imaging (OCULUS Optikgeräte GmbH, Weztlar, Germany) was conducted which revealed pachymetry of 927 microns OD and 641 microns OS. Central corneal edema with Descemet folds, as visible in [Figure 1](#f1-opth-12-1367){ref-type="fig"}, was exhibited without anterior chamber cell, in the right eye greater than the left. The patient had no known history of Fuchs dystrophy, viral prodrome or infection. Amantadine toxicity was considered and a discussion was held with her neurologist regarding discontinuation of the medication. However, given her need for amantadine, she was reluctant to discontinue the medication until an alternative treatment was identified. She returned 3 weeks later with worsening of vision to 20/125 OU, and pachymetry of 946 microns OD and 598 microns OS.

Given the disease progression, she discontinued amantadine and returned to the clinic 1 week later (Week 4 since presentation), with continued progression of edema. Visual acuity was 20/250 OD and 20/150 OS. She was monitored with serial visits, improving at Week 6 to 20/70 OD and 20/50 OS.

At 2 months (Week 8), her corneal edema had resolved and visual acuity returned to 20/30 OU, with pachymetry of 585 microns OD and 550 microns OS. Specular microscopy of both eyes with a machine unable to conduct flex-center analysis revealed severe endothelial cell loss, greater in the right eye, which subjectively appeared stable over time through subsequent analyses able to provide quantitative estimates ([Figure 2](#f2-opth-12-1367){ref-type="fig"}).

At 6 months (Week 24), she returned for a follow-up appointment with worsening of her neurological state. Therefore, she resumed amantadine at a lower dose of 300 mg by mouth daily, divided into 200 mg in the morning and 100 mg in the evening. She maintained use of topical loteprednol 0.5% twice daily in both eyes. Her visual acuity remained stable subjectively and improved objectively to 20/25 OU. Pachymetry was stable in the right eye at 586 microns and continued to improve in the left eye at 523 microns.

At month 12 (Week 48), the patient returned for repeat specular microscopy, which revealed endothelial cell counts of 609 cells/mm^2^ OD and 1,387 cells/mm^2^ OS. In light of a guttate appearance to her cornea, she enrolled in a longitudinal study of Fuchs dystrophy for which she provided a blood sample and we sequenced the CTG18.1 trinucleotide repeat in *TCF4* using methods we have previously described.[@b1-opth-12-1367] She was found not to bear the implicated repeat expansion. She continued oral amantadine, and due to changes in insurance coverage, began topical fluorometholone 0.1% twice daily in place of topical loteprednol 0.5%.

At 18 months, the patient underwent repeat specular microscopy, which continued to be stable at 627 and 1,309 cells/mm^2^ in the right and left eyes, respectively, and 649 and 1,186 cells/mm^2^ at 2.7 years, despite continuing amantadine 300 mg daily. Images were analyzed with the flex center method. Visual acuity remained stable at 20/30 bilaterally, with no corneal edema present. She remains on topical fluorometholone twice daily in both eyes.

[Table 1](#t1-opth-12-1367){ref-type="table"} delineates the progression and resolution of her corneal edema based on visual acuity, pachymetry and specular microscopy readings. [Table 2](#t2-opth-12-1367){ref-type="table"} summarizes the patterns of corneal edema described in all known cases in the literature, revealing central corneal edema as a characteristic pattern present in a slight majority of cases at time of diagnosis. Written informed consent was provided by the patient to publish case details and accompanying images. The Institutional Research Board at Johns Hopkins University School of Medicine waived the need for approval for reporting a single case.

Discussion
==========

Amantadine was first approved in 1966 for influenza prophylaxis and 3 years later, was discovered to address symptoms of Parkinson's disease. It has weak N-methyl-D-aspartate (NMDA)-type glutamate receptor antagonist and anticholinergic properties, and both increase dopamine release and block dopamine reuptake. Its antiviral properties are related to an unrelated, separate effect on the M2 proton channel, a homotetramer located in viral envelopes of influenza viruses which modulates local pH levels to promote intracellular viral functions.

While its most common adverse effects are associated with central nervous system function, including anxiety, agitation, and modulation of pre-existing epileptic or psychiatric symptoms, corneal edema is uncommon, at 0.27% in a 2-year study among veterans;[@b3-opth-12-1367] in a post-surveillance study of over 13,137 patients receiving amantadine over 2 years, 36 were newly diagnosed with either corneal edema or Fuchs dystrophy. It is notable that 73% of known cases (16 of 22) have occurred in females ([Table 2](#t2-opth-12-1367){ref-type="table"}), a predominance that is also seen in Fuchs dystrophy. It is unclear whether similar pathways may contribute to such disparity, as endothelial cell death appears to occur in both diseases.[@b20-opth-12-1367] We demonstrate here that in this case, amantadine-associated corneal edema is independent of a common genetic change prevalent in approximately two-thirds of individuals diagnosed with Fuchs dystrophy. Moreover, the resolution of edema does not support a diagnosis of Fuchs dystrophy, which progressively worsens over time. Nevertheless, more cases and similar analyses will be needed to better elucidate an association or lack thereof.

The pathophysiological mechanisms of transient edema in such cases are poorly understood; however, based on specular microscopy and histopathologic findings, endothelial cell death appears to be induced or accelerated.[@b8-opth-12-1367] In this study, we compared the temporal progression and resolution of corneal edema in two affected eyes with all reported instances of amantadine-associated corneal edema in the literature ([Table 2](#t2-opth-12-1367){ref-type="table"}) and identify characteristic patterns of edema. First, corneal edema often appears centrally and, in some cases, progresses to diffuse edema. Second, cases may be asymmetrically bilateral, a process captured with bilateral imaging.

Given the need in some cases for corneal transplantation,[@b10-opth-12-1367] early identification and cessation of amantadine will be helpful to maximize the likelihood of achieving corneal clarity. However, in instances where amantadine cannot be discontinued, as no alternative therapy is available, we describe the possibility that resuming amantadine with steroids may have assisted to maintain corneal endothelial cell density. Our findings support prior reports that demonstrated partial responses to topical and intravenous corticosteroids.[@b10-opth-12-1367] The relationship with long-term amantadine dosing is unclear; it may be that amantadine toxicity is not related to the cumulative dose, but rather potentially an alternative mechanism, such as rapid increase to a toxic level at a given point in time. In a nationwide cohort study in Taiwan of patients with Parkinson disease, a hazard ratio of 1.79 for corneal edema with amantadine use increased to 2.05 for those with a moderate dose (2,000--4,000 mg) and 2.84 for those with a high dose (\>4,000 mg).[@b21-opth-12-1367]

Conclusion
==========

Long-term outcomes of amantadine toxicity are unknown. We include here follow-up data for 32 months, the longest such interval to our knowledge. In contrast to patients whose edema returned following repeat challenge with amantadine,[@b3-opth-12-1367] this case revealed that it may be possible to tolerate a dose if necessary without development of further corneal edema. However, a single case does not equate to a recommendation, and outcomes from additional cases will be beneficial to understanding the likelihood of such benefit.
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![Serial Scheimpflug imaging of amantadine-associated corneal edema. At initial diagnosis, edema was noted to be central in distribution, worse in the right eye (**A**) than the left (**B**). After cessation, corneal edema resolved. Despite the necessity of resuming amantadine, the patient has continued to maintain corneal clarity with concurrent steroids, with resolution of edema in both right (**C**) and left (**D**) eyes, more than 2 years after initial presentation.\
**Abbreviations:** OD, oculus dextrus; OS, oculus sinister.](opth-12-1367Fig1){#f1-opth-12-1367}

![Specular microscopy reveals marked endothelial cell loss. Concurrent with the asymmetry of corneal edema at presentation, the right eye (**A**) demonstrates worse polymegethism than the left (**B**). Dark opacities, which may represent toxic byproducts, debris or pigment, provide a guttate-like appearance with slit-lamp biomicroscopy. The area is 0.1 mm^2^.](opth-12-1367Fig2){#f2-opth-12-1367}

###### 

Progression and resolution of the patient's corneal edema based on visual acuity, pachymetry and specular microscopy. Although amantadine was resumed, the patient has maintained visual acuity, central corneal thickness and endothelial cell density over a 140-week period

  Date (week)                                           Visual acuity   Pachymetry (microns)   Specular microscopy (cells/mm^2^)                                                              
  ----------------------------------------------------- --------------- ---------------------- ----------------------------------- ----- ---------------------------------------------------- -------------------------------------------------------------------------
  Week 1                                                20/125          20/60                  927                                 641                                                        
  Week 3[\*](#tfn1-opth-12-1367){ref-type="table-fn"}   20/125          20/125                 946                                 598                                                        
  Week 4                                                20/250          20/150                                                                                                                
  Week 6                                                20/70           20/50                                                                                                                 
  Week 8                                                20/30           20/30                  585                                 550   Marked endothelial cell loss (subjective analysis)   Marked endothelial cell loss, less than right eye (subjective analysis)
  Week 24                                               20/25           20/25                  586                                 523                                                        
  Week 48                                               20/30           20/40                                                            609                                                  1,387
  Week 81                                               20/40           20/50                  541                                 516   627                                                  1,309
  Week 110                                              20/30           20/30                  560                                 536   726                                                  1,138
  Week 140                                              20/30           20/30                  563                                 563   649                                                  1,186

**Note:**

Amantadine was discontinued at week 3.

**Abbreviations:** OD, oculus dexter; OS, oculus sinister; OU, oculus uterque.

###### 

Review of 22 cases of amantadine-associated corneal edema. Notably, 12 out of 22 cases of corneal edema described are central in distribution, suggesting a characteristic pattern that may progress into diffuse edema over time. Moreover, many cases are severely thickened, approaching or exceeding 1,000 microns in thickness

  \#                      Gender   Age   Pachymetry OD       Pachymetry OS       Distribution of edema in photographs   Length of amantadine therapy
  ----------------------- -------- ----- ------------------- ------------------- -------------------------------------- ------------------------------
  1[@b11-opth-12-1367]    Female   63    661                 651                 Central                                7 months
  2[@b18-opth-12-1367]    Female   64    677                 756                 Central epithelial bullae              2 years
  3[@b16-opth-12-1367]    Female   16    Unknown             Unknown             Central                                6 months
  4[@b2-opth-12-1367]     Female   77    1,000+              1,000+              Diffuse                                25 days
  5[@b4-opth-12-1367]     Female   61    810                 780                 Central                                6 years
  6[@b18-opth-12-1367]    Female   45    867                 700                 Central                                17 months
  7[@b7-opth-12-1367]     Female   68    871                 746                 No picture                             2 years
  8[@b12-opth-12-1367]    Female   40    Unable to acquire   Unable to acquire   Diffuse                                Unknown
  9[@b6-opth-12-1367]     Female   39    940                 802                 Central folds, diffuse edema           8 months
  10[@b14-opth-12-1367]   Male     43    954                 828                 Diffuse                                4 months
  11[@b10-opth-12-1367]   Female   55    688                 687                 Diffuse                                6 years
  12[@b10-opth-12-1367]   Male     57    838                 1,000               Central                                2 months
  13[@b10-opth-12-1367]   Female   44    Unknown             Unknown             Diffuse                                3 months
  14[@b15-opth-12-1367]   Female   12    851                 886                 No picture                             6 months
  15[@b15-opth-12-1367]   Female   55    930                 934                 Central                                Several years
  16[@b19-opth-12-1367]   Female   52    Unknown             Unknown             Confined to the central two-thirds     6.5 years
  17[@b5-opth-12-1367]    Female   74    Unknown             Unknown             No picture                             8 years
  18[@b13-opth-12-1367]   Male     61    Unknown             Unknown             Central                                8 months
  19[@b9-opth-12-1367]    Male     14    973                 950                 No picture                             \<1 year
  20[@b17-opth-12-1367]   Male     46    803                 911                 Central                                3 years
  21[@b1-opth-12-1367]    Male     12    917                 937                 No picture                             6 months
  22 (this study)         Female   44    946                 598                 Central                                7 years

**Abbreviations:** OD, oculus dexter; OS, oculus sinister.
